TMCnet News
GPM Announces Investigation of OvaScience, Inc.Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company") (Nasdaq: OVAS) securities pursuant or traceable to the Company's January 8, 2015 Offering and Registration Statement. Investors who have suffered losses on their investment in OvaScience securities are encouraged to contact GPM at 310-201-9150 to discuss their legal rights. The investigation focuses on whether OvaScience made materially untrue and misleading statements and omitted material information because the Company failed to disclose that OvaScience's AUGMENT procedure did not achieve a significant success rate of clinical pregnancies compared to previous rates achieved without the Company's AUGMENT procedure. Investors have suffered damages followin the sharp decline of the Company's common stock from an offering price of $50 per share, to a recent close on January 21, 2015 of $8.74 per share. If you purchased OvaScience securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160202006696/en/ |
